The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study.
 
Xinan Sheng
Speakers' Bureau - BeiGene; Junshi Pharmaceuticals; Novartis; Pfizer; RemeGen
 
Hongqian Guo
No Relationships to Disclose
 
Xin Yao
No Relationships to Disclose
 
Fangjian Zhou
No Relationships to Disclose
 
Jimin Chen
No Relationships to Disclose
 
Shun Zhang
No Relationships to Disclose
 
Juan Li
No Relationships to Disclose
 
Lei Diao
No Relationships to Disclose
 
Pei Dong
No Relationships to Disclose
 
Xiaoqing Li
No Relationships to Disclose
 
Zhewei Zhang
No Relationships to Disclose
 
Anne Chain
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Pengfei Zhu
No Relationships to Disclose
 
Weijuan Zhang
Employment - MSD
 
Ding Wang
Employment - Merck
Stock and Other Ownership Interests - Merck; Merck
Travel, Accommodations, Expenses - Qurgen
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere